@cayenne Eric Sorscher at Emory is studying the use of Trikafta in BE treatment of NTM infections in CF carriers in a small clinical trial (ID NCT05743946)
Here's a link to a the case reports that led to the trial. They used Trikafta (aka ETI) in 3 people without CF but with BE and NTM infections who all carry F508del, the most common CF mutation in the Caucasian population.
https://www.gavinpublishers.com/article/view/treating-non-cystic-fibrosis-bronchiectasis-with-cftr-modulators-early-case-reports